WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009060198) ANTI-VEGF ANTIBODY COMPOSITIONS AND METHODS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/060198    International Application No.:    PCT/GB2008/003745
Publication Date: 14.05.2009 International Filing Date: 07.11.2008
IPC:
A61K 39/395 (2006.01), A61P 35/00 (2006.01), C07K 16/22 (2006.01)
Applicants: PEREGRINE PHARMACEUTICALS, INC. [US/US]; 14272 Franklin Avenue Suite 100 Tustin, CA 92780 (US).
AFFITECH RESEARCH AS [NO/NO]; Oslo Research Park Gaustadallèen 21 N-0349 Oslo (NO).
OWEN, Deborah Jane [GB/GB]; (GB) (BB only)
Inventors: KAVLIE, Anita; (NO).
SCHLUNEGGER, Kyle; (US)
Agent: DEHNS; St Bride' s House 10 Salisbury Square London EC4Y 8JD (GB)
Priority Data:
60/987,015 09.11.2007 US
61/106,047 16.10.2008 US
61/108,023 24.10.2008 US
Title (EN) ANTI-VEGF ANTIBODY COMPOSITIONS AND METHODS
(FR) COMPOSITIONS D'ANTICORPS ANTI-VEGF ET PROCÉDÉS CORRESPONDANTS
Abstract: front page image
(EN)Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
(FR)L'invention porte sur des anticorps humains qui inhibent spécifiquement une liaison de VEGF à un seul (VEGFR2) des deux récepteurs de VEGF primaires. Les anticorps inhibent efficacement l'angiogenèse et induisent la régression de tumeur et présentent cependant une sécurité améliorée en raison de leur spécificité. La présente invention propose ainsi de nouvelles compositions à base d'anticorps humains, des procédés et des protocoles combinés pour traiter le cancer et d'autres maladies angiogéniques. L'invention porte également sur des compositions avantageuses d'immunoconjugé et sur des procédés d'utilisation des nouveaux anticorps humains spécifiques de VEGF.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)